Practice
Featured experience
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
Mastercard $1.8 billion acquisition of BVNK
We are advising Mastercard on the transaction
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We advised Sycamore Partners on the transaction
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Applied Materials $1 billion senior notes offering
The investment-grade notes are due 2031 and 2036
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Norwegian Cruise Line Holdings comprehensive refinancing transactions
The transactions included new debt, exchangeable debt, registered direct equity offerings and concurrent tender offers
Bombardier $250 million senior notes offering
The investment-grade senior notes are due 2033
Natura sale of Avon International to Regent
We are advising Natura on the sale
Century Communities $500 million senior notes offering and concurrent redemption
The high-yield notes are due 2033
GrowthCurve Capital acquisition of PlanHub
We advised GrowthCurve Capital on the transaction
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Strive Nasdaq listing and $450 million at-the-market offering
We advised Strive on its Nasdaq listing and offering